Get started
Author

Alexander James Spicer

Observed names: AJS Spicer, Alexander J Spicer, Alexander J. Spicer, Alexander Spicer
ORCID: 0000-0002-7819-1906
Observed ORCID: 0000-0002-7819-1906
OpenAlex ID: A5014797356
Correction: Corrigendum: N-terminal domain of Bothrops asper Myotoxin II Enhances the Activity of Endothelin Converting Enzyme-1 and Neprilysin
2016 · A. Ian Smith, Niwanthi W. Rajapakse, et al. · Scientific Reports · 129
PDF
Droplet Digital PCR for Mutation Detection in Formalin-Fixed, Paraffin-Embedded Melanoma Tissues
2018 · Ashleigh C. McEvoy, Benjamin A. Wood, et al. · Journal of Molecular Diagnostics · 47
Mind the gap: closing the growing chasm between academia and industry
2022 · Alexander J. Spicer, Pierre-Albert Colcomb, et al. · Nature Biotechnology · 19
N-terminal domain of Bothrops asper Myotoxin II Enhances the Activity of Endothelin Converting Enzyme-1 and Neprilysin
2016 · A. Ian Smith, Niwanthi W. Rajapakse, et al. · Scientific Reports · 12
PDF
Why Haven’t We Found an Effective Treatment for COVID-19?
2021 · Alexander James Spicer, Sirpa Jalkanen · Frontiers in Immunology · 11
PDF
Stimulating the Activity of Amyloid-Beta Degrading Enzymes: A Novel Approach for the Therapeutic Manipulation of Amyloid-Beta Levels
2016 · Sanjaya Kuruppu, Niwanthi W. Rajapakse, et al. · Journal of Alzheimer s Disease · 11
Review of the impact of the FDA’s Fast Track Designation on biotechnology companies’ share prices
2023 · Joab Williamson, Alexander James Spicer · Drug Discovery Today · 7
Unveiling the impacts of FDA Breakthrough Therapy Designation: a dual-perspective examination of economic and developmental outcomes for biotechnology companies
2024 · Joab Williamson, Alexander James Spicer, et al. · Drug Discovery Today · 6
The Effect of the RMAT Designation on Biotechnology Stock Prices, Drug Development Timelines and Outcomes: An Empirical Analysis
2024 · Joab Williamson, Alexander James Spicer, et al. · Journal of Pharmaceutical Research International · 4
Targeting CD73 and correcting adenosinergic signaling in critically ill patients
2026 · Justin Mark Lunderberg, Alexander James Spicer, et al. · Frontiers in Pharmacology · 3
PDF
Evaluating the impact of the FDA’s orphan drug designation on share prices of biotechnology companies
2023 · Joab Williamson, Alexander James Spicer · Drug Discovery Today · 2
Financial Dynamics in Cell and Gene Therapy Development: Navigating Valuation and Fundraising Challenges
2024 · Joab Williamson, Alexander Spicer, et al. · Applied Drug Research Clinical Trials and Regulatory Affairs · 1
PDF
Rare disease benchmarks: Investment professionals’ accuracy and beliefs
2026 · Jonathan Ilicki, Alexander J. Spicer · Drug Discovery Today
The Ethics of Optimism: Managing Investor Expectations in Biotech and Pharma
2025 · Joab Williamson, Alexander Spicer · Springer eBooks
Phase I/II Study to Evaluate the Safety, Feasibility, and Efficacy of FP-1201 (Intravenous Interferon-Beta-1a) to Prevent Toxicities after CD19-Directed CAR T-Cell Therapy: Trial in Progress
2023 · Emily C Liang, Erik L Kimble, et al. · Blood
PDF
752 Developing biomarkers for bexmarilimab, a novel macrophage-guided immunotherapy, in advanced solid tumors to select patients and confirm mechanism of action
2023 · Alexander J Spicer, Elisa M Vourninen, et al. · Journal for ImmunoTherapy of Cancer
PDF
Ps-bpb02-7: the Role of Neutrophil to Lymphocyte Ratio as Predictive Biomarker in Acute Coronary Syndrome: a Systematic Review and Meta-analysis
2023 · Elona Greca, Alexander James Spicer, et al. · Journal of Hypertension
Letter to the Editor: Autoantibodies to Type I Interferons: The Chicken or the Egg?
2022 · Alexander J. Spicer, Juho Jalkanen, et al. · Journal of Interferon & Cytokine Research
Induction of CD73 prevents death after emergency open aortic surgery
2022 · AJS Spicer, MV Venermo, et al. · Cardiovascular Research
Works count: 19
Citation count: 252
H-index: 7
I10-index: 6
Year
Topic
Type